BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31653061)

  • 1. Prolactin-Releasing Peptide: Physiological and Pharmacological Properties.
    Pražienková V; Popelová A; Kuneš J; Maletínská L
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31653061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of lipidized analogs of prolactin-releasing peptide with a modified C- terminal aromatic ring.
    Prazienkova V; Ticha A; Blechova M; Spolcova A; Zelezna B; Maletinska L
    J Physiol Pharmacol; 2016 Feb; 67(1):121-8. PubMed ID: 27010901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palmitoylation of Prolactin-Releasing Peptide Increased Affinity for and Activation of the GPR10, NPFF-R2 and NPFF-R1 Receptors: In Vitro Study.
    Karnošová A; Strnadová V; Holá L; Železná B; Kuneš J; Maletínská L
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological properties of prolactin-releasing peptide analogs with a modified aromatic ring of a C-terminal phenylalanine amide.
    Maletínská L; Spolcová A; Maixnerová J; Blechová M; Zelezná B
    Peptides; 2011 Sep; 32(9):1887-92. PubMed ID: 21872625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular Signaling and Anti-Apoptotic Effects of Prolactin-Releasing Peptide and Its Analog on SH-SY5Y Cells.
    Zmeškalová A; Popelová A; Exnerová A; Železná B; Kuneš J; Maletínská L
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of prolactin-releasing peptide: binding, signaling and hormone secretion in rodent pituitary cell lines endogenously expressing its receptor.
    Maixnerová J; Špolcová A; Pýchová M; Blechová M; Elbert T; Rezáčová M; Zelezná B; Maletínská L
    Peptides; 2011 Apr; 32(4):811-7. PubMed ID: 21185342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin-releasing peptide effects in the rat brain are mediated through the Neuropeptide FF receptor.
    Ma L; MacTavish D; Simonin F; Bourguignon JJ; Watanabe T; Jhamandas JH
    Eur J Neurosci; 2009 Oct; 30(8):1585-93. PubMed ID: 19821834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated peripheral administration of lipidized prolactin-releasing peptide analog induces c-fos and FosB expression in neurons of dorsomedial hypothalamic nucleus in male C57 mice.
    Pirník Z; Kolesárová M; Železná B; Maletínská L
    Neurochem Int; 2018 Jun; 116():77-84. PubMed ID: 29601847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel lipidized analogs of prolactin-releasing peptide have prolonged half-lives and exert anti-obesity effects after peripheral administration.
    Maletínská L; Nagelová V; Tichá A; Zemenová J; Pirník Z; Holubová M; Špolcová A; Mikulášková B; Blechová M; Sýkora D; Lacinová Z; Haluzík M; Železná B; Kuneš J
    Int J Obes (Lond); 2015 Jun; 39(6):986-93. PubMed ID: 25771926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prolactin-releasing peptide receptor (GPR10) regulates body weight homeostasis in mice.
    Gu W; Geddes BJ; Zhang C; Foley KP; Stricker-Krongrad A
    J Mol Neurosci; 2004; 22(1-2):93-103. PubMed ID: 14742914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin-releasing Peptide mediates cholecystokinin-induced satiety in mice.
    Bechtold DA; Luckman SM
    Endocrinology; 2006 Oct; 147(10):4723-9. PubMed ID: 16794001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous mammalian RF-amide peptides, including PrRP, kisspeptin and 26RFa, modulate nociception and morphine analgesia via NPFF receptors.
    Elhabazi K; Humbert JP; Bertin I; Schmitt M; Bihel F; Bourguignon JJ; Bucher B; Becker JA; Sorg T; Meziane H; Petit-Demoulière B; Ilien B; Simonin F
    Neuropharmacology; 2013 Dec; 75():164-71. PubMed ID: 23911743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the binding of [(125)I]-human prolactin releasing peptide (PrRP) to GPR10, a novel G protein coupled receptor.
    Langmead CJ; Szekeres PG; Chambers JK; Ratcliffe SJ; Jones DN; Hirst WD; Price GW; Herdon HJ
    Br J Pharmacol; 2000 Oct; 131(4):683-8. PubMed ID: 11030716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hindbrain is a site of energy balance action for prolactin-releasing peptide: feeding and thermic effects from GPR10 stimulation of the nucleus tractus solitarius/area postrema.
    Davis XS; Grill HJ
    Psychopharmacology (Berl); 2018 Aug; 235(8):2287-2301. PubMed ID: 29796829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Search for lipidized PrRP analogs with strong anorexigenic effect: In vitro and in vivo studies.
    Strnadová V; Karnošová A; Blechová M; Neprašová B; Holá L; Němcová A; Myšková A; Sýkora D; Železná B; Kuneš J; Maletínská L
    Neuropeptides; 2023 Apr; 98():102319. PubMed ID: 36669365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of prolactin-releasing peptide and RFamide related peptides in the control of stress and food intake.
    Takayanagi Y; Onaka T
    FEBS J; 2010 Dec; 277(24):4998-5005. PubMed ID: 21126313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of novel palmitoylated prolactin-releasing peptide analogs on metabolic changes in mice with diet-induced obesity.
    Pražienková V; Holubová M; Pelantová H; Bugáňová M; Pirník Z; Mikulášková B; Popelová A; Blechová M; Haluzík M; Železná B; Kuzma M; Kuneš J; Maletínská L
    PLoS One; 2017; 12(8):e0183449. PubMed ID: 28820912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin-releasing peptide: a new tool for obesity treatment.
    Kuneš J; Pražienková V; Popelová A; Mikulášková B; Zemenová J; Maletínská L
    J Endocrinol; 2016 Aug; 230(2):R51-8. PubMed ID: 27418033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropeptide FF and prolactin-releasing peptide decrease cortical excitability through activation of NPFF receptors.
    Buffel I; Meurs A; Portelli J; Raedt R; De Herdt V; Sioncke L; Wadman W; Bihel F; Schmitt M; Vonck K; Bourguignon JJ; Simonin F; Smolders I; Boon P
    Epilepsia; 2015 Mar; 56(3):489-98. PubMed ID: 25684325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect.
    Alexopoulou F; Bech EM; Pedersen SL; Thorbek DD; Leurs U; Rudkjær LCB; Fosgerau K; Hansen HH; Vrang N; Jelsing J; Elster L
    Sci Rep; 2022 Feb; 12(1):1696. PubMed ID: 35105898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.